Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China
Executive Summary
AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea, unless perhaps it’s just a negotiating ploy.
You may also be interested in...
Industry Urged To Watch And Wait For US/China Tariff War To Blow Over
Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.
U.S-China Trade War Heats Up; Should Health Sector Start Worrying?
As US prepares new tariffs, industry tries to to stay optimistic about business prospects in China.
PhRMA, BIO Mum On Trump’s Tariffs
While pressing the US trade representative for stronger IP protection, groups representing the brand biopharma sector remain silent on the Trump administration’s plan to hit China with 25% tariffs.